Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Urol Oncol ; 37(5): 297.e1-297.e7, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30737160

RESUMO

OBJECTIVES: Small ribosomal protein subunit 7 (RPS7) is an important structural components of the ribosome involved in protein synthesis, previous studies demonstrated that RPS7 was associated with several malignancies, but the role of RPS7 in prostate cancer (PCa) remains unclear. To decipher such a puzzle, in the current study, we deciphered the role and mechanism of RPS7 during the progression of PCa. MATERIAL AND METHODS: In this study, the expression of mRNA was performed by quantitative real-time PCR. The protein level was identified by Western blotting. Kaplan-Meier survival analysis was demonstrated the relation between the abnormal expression of RPS7 mRNA and the overall survival. Cell proliferation was assessed by MTT assay and cell counting, meanwhile, cell migration was checked by transwell assay. RESULTS: RPS7 is higher expressed in PCa (p < 0.001), and the overexpression of RPS7 is closely associated with poor outcome of PCa patients after radical prostatectomy (p < 0.001). Inhibition the expression of RPS7 with a specific RPS7 siRNA could markedly attenuate prostate tumor growth and migration (p < 0.05). Mechanistic data reveals that inhibition of RPS7 could up-regulate the epithelial protein marker, E-cadherin (p < 0.05), and down-regulate the mesenchymal protein markers, such as N-cadherin and Snail (p < 0.001). CONCLUSIONS: RPS7 is a newly verified tumor promoter in PCa, and promotes cell migration by targeting epithelial-to-mesenchymal transitionpathway. Thus, inhibition of RPS7-epithelial to-mesenchymal transition signaling might represent a prospective approach toward limiting prostate tumor progression.


Assuntos
Movimento Celular , Transição Epitelial-Mesenquimal/fisiologia , Neoplasias da Próstata/patologia , Subunidades Proteicas/fisiologia , Proteínas Ribossômicas/fisiologia , Células Cultivadas , Humanos , Masculino
2.
Toxicol Lett ; 288: 136-142, 2018 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-29462692

RESUMO

Antimony is a widely used heavier pnictogens in industry, and its toxicity has been a matter of concern. Although previous studies have suggested that antimony may have the function as either a tumor suppressor or an oncogene in several cancers, the molecular basis underlying antimony-mediated transformation is still unclear. In the current study, we attempt to elucidate the potential role of antimony in the development of prostate cancer. Our results showed that the concentration of antimony was much higher in serum of prostate cancer patients, and was closely associated with poor outcome of patients who underwent radical prostatectomy. Additionally, low dose of antimony could promote proliferation and invasion of androgen-dependent prostate cancer cell line LNCaP cells in vitro and in vivo. The mechanistic studies demonstrated that exposure to antimony triggered the phosphorylation of androgen receptor (AR), which transcriptionally regulates the expression of androgen-related targets, including PSA and NKX3.1. Overall, our results unearthed that antimony could promote tumor growth by mimicking androgen activity in androgen-dependent prostate cancer cells. Therefore, these findings expanded our understanding on the molecular mechanism of antimony in tumorigenesis and tumor progression of prostate cancer, and it appears to be an inspiring strategy to restrain prostate cancer by inhibiting antimony-induced androgen-like effects.


Assuntos
Androgênios/farmacologia , Antimônio/farmacologia , Neoplasias da Próstata/patologia , Antagonistas de Androgênios/farmacologia , Animais , Antimônio/sangue , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Proteínas de Homeodomínio/biossíntese , Proteínas de Homeodomínio/efeitos dos fármacos , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Fosforilação , Antígeno Prostático Específico/biossíntese , Antígeno Prostático Específico/efeitos dos fármacos , Prostatectomia , Neoplasias da Próstata/sangue , Neoplasias da Próstata/cirurgia , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Receptores Androgênicos/efeitos dos fármacos , Fatores de Transcrição/biossíntese , Fatores de Transcrição/efeitos dos fármacos , Resultado do Tratamento
3.
Beijing Da Xue Xue Bao Yi Xue Ban ; 43(4): 565-9, 2011 Aug 18.
Artigo em Chinês | MEDLINE | ID: mdl-21844968

RESUMO

OBJECTIVE: To describe early complications (within 90 days) after radical cystectomy and to analyze the associated specific risk factors. METHODS: The clinical data from 208 consecutive cases of muscle invasive bladder cancer were collected and reviewed. Potential variables predictive of early morbidity were retrospectively analyzed. RESULTS: Of the 208 subjects, 160 (76.9%)developed at least 1 postoperative complication and 46 (22.2%) at least 2 complications. The most frequent complications presented were blood loss (75 cases), post-operative renal insufficiency (31 cases), and intestinal obstruction (29 cases). In univariate analysis, operative time, hypertension and preoperative creatinine level were associated with the development of complications. On multivariate analysis, operative time, preoperative creatinine level were the significant factors. CONCLUSION: Morbidity remains high after radical cystectomy. The operative time, preoperative creatinine level and hypertension may be associated with the postoperative complications. Acknowledgement of the patients' specific risk factors and monitoring perioperative processes may incrementally reduce risks and improve outcomes of the patients.


Assuntos
Carcinoma de Células de Transição/cirurgia , Cistectomia/efeitos adversos , Complicações Pós-Operatórias/epidemiologia , Neoplasias da Bexiga Urinária/cirurgia , Idoso , Perda Sanguínea Cirúrgica , Carcinoma de Células de Transição/patologia , Creatinina/sangue , Cistectomia/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Insuficiência Renal/etiologia , Estudos Retrospectivos , Fatores de Risco , Neoplasias da Bexiga Urinária/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA